Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

This study examines why some patients with lung squamous cell carcinoma (a type of non-small cell lung cancer) respond better than others to a pre-surgery treatment combining chemotherapy and immunotherapy. Researchers will analyze tumor samples to find biological markers that predict response. **You may be eligible if...** - You are between 40 and 80 years old - You have been diagnosed with lung squamous cell carcinoma that is locally advanced but can be surgically removed - You have not had any prior cancer treatment - You received three cycles of neoadjuvant (pre-surgery) treatment with an anti-PD-1 drug plus chemotherapy (nab-paclitaxel and carboplatin) - You have pre-treatment tissue samples available **You may NOT be eligible if...** - Your cancer has spread to the brain - You have an immune deficiency condition or recently used immune-suppressing drugs - You have uncontrolled high blood pressure - You have pulmonary fibrosis or interstitial lung disease Talk to your doctor to see if this trial is right for you.